Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
“We published a reflective article on why the uptake of gene therapy in hemophilia is less than expected. It’s not due to lack of interest in gene therapy in general by patients and health care providers, as some have alleged, but related to more complex problems including the differing benefit/risk balance of individual gene therapies and need for more creative reimbursement frameworks. Medicines with strong efficacy and safety have been, and will continue to be embraced by the community. We look forward to advancing technological improvements in gene therapies, including gene editing, especially for hemophilia A, and to more enthusiasm of biopharma to reach 85% of the world having substandard or no treatment.”
To learn more, follow the link.
Read the full article here.
Article: Why is the uptake of gene therapy in hemophilia less than expected?
Authors:
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion